BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37071208)

  • 1. The HDAC inhibitor domatinostat induces type I interferon α in Merkel cell carcinoma by HES1 repression.
    Srinivas N; Song L; Lei KC; Gravemeyer J; Furtmann F; Gambichler T; Becker JC; Sriram A
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8267-8277. PubMed ID: 37071208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells.
    Song L; Bretz AC; Gravemeyer J; Spassova I; Muminova S; Gambichler T; Sriram A; Ferrone S; Becker JC
    J Invest Dermatol; 2021 Apr; 141(4):903-912.e4. PubMed ID: 33002502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
    Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
    Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
    Roca MS; Moccia T; Iannelli F; Testa C; Vitagliano C; Minopoli M; Camerlingo R; De Riso G; De Cecio R; Bruzzese F; Conte M; Altucci L; Di Gennaro E; Avallone A; Leone A; Budillon A
    J Exp Clin Cancer Res; 2022 Mar; 41(1):83. PubMed ID: 35241126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.
    Ritter C; Fan K; Paschen A; Reker Hardrup S; Ferrone S; Nghiem P; Ugurel S; Schrama D; Becker JC
    Sci Rep; 2017 May; 7(1):2290. PubMed ID: 28536458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Merkel cell polyomavirus oncoproteins induce microRNAs that suppress multiple autophagy genes.
    Kumar S; Xie H; Shi H; Gao J; Juhlin CC; Björnhagen V; Höög A; Lee L; Larsson C; Lui WO
    Int J Cancer; 2020 Mar; 146(6):1652-1666. PubMed ID: 31180579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of PI3K signaling in Merkel cell carcinoma.
    Nardi V; Song Y; Santamaria-Barria JA; Cosper AK; Lam Q; Faber AC; Boland GM; Yeap BY; Bergethon K; Scialabba VL; Tsao H; Settleman J; Ryan DP; Borger DR; Bhan AK; Hoang MP; Iafrate AJ; Cusack JC; Engelman JA; Dias-Santagata D
    Clin Cancer Res; 2012 Mar; 18(5):1227-36. PubMed ID: 22261808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of cancer cell line representativeness using microarrays for Merkel cell carcinoma.
    Daily K; Coxon A; Williams JS; Lee CR; Coit DG; Busam KJ; Brownell I
    J Invest Dermatol; 2015 Apr; 135(4):1138-1146. PubMed ID: 25521454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma.
    Ritter C; Fan K; Paulson KG; Nghiem P; Schrama D; Becker JC
    Sci Rep; 2016 Feb; 6():21678. PubMed ID: 26902929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Merkel cell polyomavirus-negative Merkel cell carcinoma is associated with JAK-STAT and MEK-ERK pathway activation.
    Iwasaki T; Hayashi K; Matsushita M; Nonaka D; Kohashi K; Kuwamoto S; Umekita Y; Oda Y
    Cancer Sci; 2022 Jan; 113(1):251-260. PubMed ID: 34724284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RB1 is the crucial target of the Merkel cell polyomavirus Large T antigen in Merkel cell carcinoma cells.
    Hesbacher S; Pfitzer L; Wiedorfer K; Angermeyer S; Borst A; Haferkamp S; Scholz CJ; Wobser M; Schrama D; Houben R
    Oncotarget; 2016 May; 7(22):32956-68. PubMed ID: 27121059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin is a therapeutic target in Merkel cell carcinoma.
    Arora R; Shuda M; Guastafierro A; Feng H; Toptan T; Tolstov Y; Normolle D; Vollmer LL; Vogt A; Dömling A; Brodsky JL; Chang Y; Moore PS
    Sci Transl Med; 2012 May; 4(133):133ra56. PubMed ID: 22572880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma.
    Paulson KG; Tegeder A; Willmes C; Iyer JG; Afanasiev OK; Schrama D; Koba S; Thibodeau R; Nagase K; Simonson WT; Seo A; Koelle DM; Madeleine M; Bhatia S; Nakajima H; Sano S; Hardwick JS; Disis ML; Cleary MA; Becker JC; Nghiem P
    Cancer Immunol Res; 2014 Nov; 2(11):1071-9. PubMed ID: 25116754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6-7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A.
    Guadagni S; Farina AR; Cappabianca LA; Sebastiano M; Maccarone R; Zelli V; Clementi M; Chiominto A; Bruera G; Ricevuto E; Fiorentini G; Sarti D; Mackay AR
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma.
    Kadletz L; Bigenzahn J; Thurnher D; Stanisz I; Erovic BM; Schneider S; Schmid R; Seemann R; Birner P; Heiduschka G
    Head Neck; 2016 Apr; 38 Suppl 1():E1918-25. PubMed ID: 26713885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.
    Church C; Pulliam T; Longino N; Park SY; Smythe KS; Makarov V; Riaz N; Jing L; Amezquita R; Campbell JS; Gottardo R; Pierce RH; Choi J; Chan TA; Koelle DM; Nghiem P
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36252564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.
    Kannan A; Lin Z; Shao Q; Zhao S; Fang B; Moreno MA; Vural E; Stack BC; Suen JY; Kannan K; Gao L
    Oncotarget; 2016 Feb; 7(6):6576-92. PubMed ID: 26536665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of Merkel cell polyomavirus positivity with PDGFRα mutations and survivin expression in Merkel cell carcinoma.
    Batinica M; Akgül B; Silling S; Mauch C; Zigrino P
    J Dermatol Sci; 2015 Jul; 79(1):43-9. PubMed ID: 25936870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I and II IFNs inhibit Merkel cell carcinoma via modulation of the Merkel cell polyomavirus T antigens.
    Willmes C; Adam C; Alb M; Völkert L; Houben R; Becker JC; Schrama D
    Cancer Res; 2012 Apr; 72(8):2120-8. PubMed ID: 22389452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.